Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription.
Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, Taipaleenmäki H, Ben-Batalla I, Scheller M, Loges S, Knapp S, Hesse E, Chiang CM, Grundhoff A, Johnsen SA. Nagarajan S, et al. Among authors: johnsen sa. Cell Rep. 2014 Jul 24;8(2):460-9. doi: 10.1016/j.celrep.2014.06.016. Epub 2014 Jul 10. Cell Rep. 2014. PMID: 25017071 Free PMC article.
BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells.
Nagarajan S, Bedi U, Budida A, Hamdan FH, Mishra VK, Najafova Z, Xie W, Alawi M, Indenbirken D, Knapp S, Chiang CM, Grundhoff A, Kari V, Scheel CH, Wegwitz F, Johnsen SA. Nagarajan S, et al. Among authors: johnsen sa. Nucleic Acids Res. 2017 Apr 7;45(6):3130-3145. doi: 10.1093/nar/gkw1276. Nucleic Acids Res. 2017. PMID: 27980063 Free PMC article.
CDK4 inhibition diminishes p53 activation by MDM2 antagonists.
Sriraman A, Dickmanns A, Najafova Z, Johnsen SA, Dobbelstein M. Sriraman A, et al. Among authors: johnsen sa. Cell Death Dis. 2018 Sep 11;9(9):918. doi: 10.1038/s41419-018-0968-0. Cell Death Dis. 2018. PMID: 30206211 Free PMC article.
Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
Patzak MS, Kari V, Patil S, Hamdan FH, Goetze RG, Brunner M, Gaedcke J, Kitz J, Jodrell DI, Richards FM, Pilarsky C, Gruetzmann R, Rümmele P, Knösel T, Hessmann E, Ellenrieder V, Johnsen SA, Neesse A. Patzak MS, et al. Among authors: johnsen sa. EBioMedicine. 2019 Feb;40:394-405. doi: 10.1016/j.ebiom.2019.01.037. Epub 2019 Jan 30. EBioMedicine. 2019. PMID: 30709769 Free PMC article.
Perturbing Enhancer Activity in Cancer Therapy.
Hamdan FH, Johnsen SA. Hamdan FH, et al. Among authors: johnsen sa. Cancers (Basel). 2019 May 7;11(5):634. doi: 10.3390/cancers11050634. Cancers (Basel). 2019. PMID: 31067678 Free PMC article. Review.
139 results